Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
Pharmaceutical
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting...
CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11
BERKELEY HEIGHTS, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health
New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and...
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform TechnologyOXNARD, Calif., July 28,...
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Phase 2a trial initiation planned for the first half of 2023 subject to IND clearance and available capitalNEWTON, Mass. and...
Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023NEWTON, Mass. and GENEVA, July 28, 2022...
Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe
EMA Guidance Provides Clear Path Forward for Quoin’s Netherton Syndrome Product in EuropeASHBURN, Va., July 28, 2022 (GLOBE NEWSWIRE) --...
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a...
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical...
Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical...
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for...
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials...
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network
SAN FRANCISCO and NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing...
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug...
MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ETNEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics,...